← Back to patent-cliff list
Cyclobenzaprine HCl sublingual tablets (Tonix Pharmaceuticals)
Tier C — Watch / tradeCyclobenzaprine HCl sublingual tablets (Tonix Pharmaceuticals)
Vela Pharmaceuticals Inc
Originator
2025
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：HRH1, 5-HT2A, ADRA2
Brand：Tonmya
Indications (approved)：Fibromyalgia
Regional status
US
Approved
2025-08-15
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Cyclobenzaprine HCl sublingual tablets (Tonix Pharmaceuticals)?
Approved indications include: Fibromyalgia.
When does the Cyclobenzaprine HCl sublingual tablets (Tonix Pharmaceuticals) patent expire?
No public expiry year is available for Cyclobenzaprine HCl sublingual tablets (Tonix Pharmaceuticals) yet; this page updates once verified.
How do I get a quote for Cyclobenzaprine HCl sublingual tablets (Tonix Pharmaceuticals) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01